<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104359</url>
  </required_header>
  <id_info>
    <org_study_id>COL2021-001</org_study_id>
    <nct_id>NCT05104359</nct_id>
  </id_info>
  <brief_title>COVID-19 Quantitative Antibody Titers &amp; Booster Vaccinations</brief_title>
  <official_title>Should COVID-19 Quantitative Antibody Titers be Implemented to Guide COVID-19 Booster Vaccinations Regardless of HIV Status, Immunosuppression, or Age?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epividian</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epividian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study aiming at describing COVID-19 vaccination outcomes among&#xD;
      HIV-positive and HIV-negative individuals, using electronic health records to observe their&#xD;
      usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig&#xD;
      spike antibody measurements). Rates of antibody level decay after vaccination will be&#xD;
      assessed. The efficacy of using antibody levels to help guide the timing of booster doses&#xD;
      among HIV-negative and HIV-positive patients will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess levels of COVID-19 vaccine response through measuring&#xD;
      surrogate Ig spike antibody measurements, to determine the rates of antibody level decay&#xD;
      after vaccination, and to measure the efficacy of utilizing these antibody measurements to&#xD;
      help guide the timing of booster doses among HIV-negative and HIV-positive patients.&#xD;
&#xD;
      The study population will include adults who were fully vaccinated against SARS-CoV-2 virus&#xD;
      (i.e., two doses of Pfizer or Moderna vaccines or one dose of the J&amp;J vaccine), and have&#xD;
      received a Roche SARS-CoV-2 Semi-Quant Spike Ig Ab test at least 3 weeks after full&#xD;
      vaccination as part of their usual clinical care at AHF Midtown Manhattan Healthcare Center.&#xD;
&#xD;
      Incidence rates of COVID vaccine response levels (i.e., adequate, low, non-response) will be&#xD;
      estimated using univariate Poisson regression, overall and by vaccine type. Among individuals&#xD;
      with at least two antibody measurements, rates of antibody levels decay will be estimated&#xD;
      using univariate linear regression, overall and stratified by HIV status, vaccine type and&#xD;
      baseline CD4 cell count. In the sub-population of individuals who received a COVID vaccine&#xD;
      booster, vaccination and antibody response will be characterized at least 3 weeks after the&#xD;
      booster is received. Univariate linear regression will be used to estimate rates of antibody&#xD;
      levels decay, among individuals with at least two antibody measurements, including one after&#xD;
      the booster dose. Rates of response decay will be produced overall, and stratified by HIV&#xD;
      status, booster type and baseline CD4 cell count.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Response</measure>
    <time_frame>&gt;21 days</time_frame>
    <description>Levels of Roche SARS-CoV-2 Semi-Quant Spike Ig antibody</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>COVID-19 Vaccines</condition>
  <condition>Immunogenicity, Vaccine</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals presenting for care at AHF Midtown Manhattan Healthcare Center who received&#xD;
        COVID-19 vaccination and antibody testing; followed through their electronic health records&#xD;
        in the OPERA Observational Database.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cared for at AHF Midtown Manhattan Healthcare Center and followed in the OPERA&#xD;
             observational database&#xD;
&#xD;
          -  Active in care in the last 24 months&#xD;
&#xD;
          -  Fully vaccinated against SARS-CoV-2 virus, implemented as 21 days after the second&#xD;
             Pfizer or Moderna injections, 21 days after the one J&amp;J injection&#xD;
&#xD;
          -  Received a Roche SARS-CoV-2 Semi-Quant Spike Ig AB test after full vaccination as&#xD;
             usual clinical care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unvaccinated or partially vaccinated against SARS-CoV-2 virus&#xD;
&#xD;
          -  Never tested with a SARS-CoV-2 Semi-Quant Total AB test after full vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ricky Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHF Midtown Manhattan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHD Manhattan Midtown HCC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Observational</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Antibody</keyword>
  <keyword>Booster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT05104359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

